Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Mee...
15 March 2018 - 10:00PM
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing oral therapies that target the various phases of cell
cycle control for the treatment of cancer and other serious
disorders, today announced that two presentations regarding CYC065,
the Company’s novel CDK inhibitor, have been selected for
presentation at the upcoming American Association for Cancer
Research (AACR) Annual Meeting to be held April 14-18, 2018 in
Chicago.
Clinical data from part 1 of an ongoing,
first-in-human, Phase 1, dose escalation study of CYC065 has been
selected for oral presentation. Details are as follows:
Title: |
|
Phase I safety,
pharmacokinetic and pharmacodynamic study of CYC065, a
cyclin dependent kinase inhibitor, in patients with advanced
cancers (NCT02552953) |
Category: |
|
Phase I Adult Clinical
Trials |
Session: |
|
CTMS01 - New Treatment
Approaches for Breast and Ovarian Cancer |
Abstract #: |
|
CT037 |
Location: |
|
Room N427 - McCormick
Place North (Level 4) |
Date and Time: |
|
Sunday, April 15, 2018,
3:00 PM - 5:00 PM |
The abstract is embargoed at this time and will
be made available in accordance with AACR rules at
http://www.abstractsonline.com/pp8/#!/4562/presentation/11142.
Preclinical data by academic collaborators of
the Company evaluating the rationale for potential combination
regimens of CYC065 and venetoclax, a Bcl-2 inhibitor approved for
patients with certain chronic lymphocytic leukemias (CLL) under
conditions that mimic the lymph node tumor microenvironment, have
been selected for a poster presentation. Details are as
follows:
Title: |
|
Strategic combination
of the cyclin-dependent kinase inhibitor CYC065 with
venetoclax to target anti-apoptotic proteins in chronic
lymphocytic leukemia |
Category: |
|
Experimental and
Molecular Therapeutics |
Session: |
|
PO.ET07.03 - Receptor
Targeting and the Tumor Microenvironment |
Abstract #: |
|
3905/ 5 |
Location: |
|
McCormick Place South,
Exhibit Hall A, Poster Section 38 |
Date and Time: |
|
Tuesday, April 17,
2018, 8:00 AM - 12:00 PM |
The abstract is available at
www.abstractsonline.com/pp8/#!/4562/presentation/4821.
About CYC065
CYC065, a second generation CDK2/9 inhibitor, is
being evaluated in a first-in-human, Phase 1 trial in patients with
advanced solid tumors. It is mechanistically similar but has higher
dose potency, in vitro and in vivo, and improved properties
compared to seliciclib, a first generation CDK inhibitor. Similarly
to FDA approved CDK4/6 inhibitors, CYC065 may be most useful in
combination with other anticancer drugs, including Bcl-2
inhibitors, such as venetoclax, or HER2 inhibitors, such as
trastuzumab. Preclinical data show that CYC065 may benefit
patients with adult and pediatric hematological malignancies,
including acute myeloid leukemias (AML), acute lymphocytic
leukemias (ALL), and in particular those with MLL rearrangements,
chronic lymphocytic leukemias (CLL), B-cell lymphomas, multiple
myelomas, and certain solid tumors, including breast and uterine
cancers, and neuroblastomas.
About Cyclacel Pharmaceuticals,
Inc.
Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle, transcriptional
regulation and DNA damage response biology to develop innovative,
targeted medicines for cancer and other proliferative diseases.
Cyclacel's transcriptional regulation program is evaluating CYC065,
a CDK inhibitor, in patients with advanced cancers. The DNA damage
response program is evaluating a sequential regimen of sapacitabine
and seliciclib, a CDK inhibitor, in patients with BRCA positive,
advanced solid cancers. Cyclacel's strategy is to build a
diversified biopharmaceutical business focused in hematology and
oncology based on a pipeline of novel drug candidates. For
additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy,
safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding
regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual
results to differ materially include the risk that product
candidates that appeared promising in early research and clinical
trials do not demonstrate safety and/or efficacy in larger-scale or
later clinical trials, trials may have difficulty enrolling,
Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues,"
"forecast," "designed," "goal," or the negative of those words or
other comparable words to be uncertain and forward-looking. For a
further list and description of the risks and uncertainties the
Company faces, please refer to our most recent Annual Report on
Form 10-K and other periodic and other filings we file with the
Securities and Exchange Commission and are available at
www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts |
|
Company: |
Paul McBarron, (908)
517-7330, pmcbarron@cyclacel.com |
Investor
Relations: |
Russo Partners LLC,
Alexander Fudukidis, (646) 942-5632, |
|
alex.fudukidis@russopartnersllc.com |
© Copyright 2018 Cyclacel Pharmaceuticals, Inc.
All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks
of Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Apr 2024 to May 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From May 2023 to May 2024